Potential link between C3a, C3b and endothelial progenitor cells in resistant hypertension

American Journal of the Medical Sciences

Volumn 339, Issue 5, 2010, Pages 415-419

  Magen, Eli ^a   Feldman, Arie ^a   Cohen, Ziona ^a   Alon, Dora Ben ^a   Linov, Lina ^a   Mishal, Joseph ^a   Schlezinger, Menachem ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

C3a; Complement; Endothelial; Hypertension; Progenitor; Resistant

Indexed keywords

ANTIHYPERTENSIVE AGENT; CD34 ANTIGEN; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; GENE ACTIVATION; HUMAN; HYPERTENSION; MALE; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; STEM CELL; SYSTOLIC BLOOD PRESSURE;

ADULT; BIOLOGICAL MARKERS; BLOOD PRESSURE; COMPLEMENT C3A; COMPLEMENT C3B; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; STEM CELLS;

EID: 77952280602     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181d7d496     Document Type: Article

References (23)

1. Cifkova R, Erdine S, Fagard R. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003;21:1779-86.
2. Engstrom G, Hedblad B, Berglund G, et al. Plasma levels of complement C3 is associated with development of hypertension: a longitudinal cohort study. J Hum Hypertens 2007;21:276-82.
3. Bozzoli C, Muscari A, Puddu GM, et al. Association of serum C3 and essential hypertension. G Ital Cardiol 1992;22:1361-6.
4. Schaadt O, Sorensen H, Krogsgaard AR. Association between the C3F-gene and essential hypertension. Clin Sci (Lond) 1981; 61 (suppl 7) : 363s-5s.
5. Thorand B, Lowel H, Schneider A, et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med 2003;163:93-9.
6. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593-600.
7. Reca R, Mastellos D, Majka M, et al. Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. Blood 2003;101:3784-93.
8. Ratajczak J, Reca R, Kucia M, et al. Mobilization studies in mice deficient in either C3 or C3a receptor (C3aR) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow. Blood 2004;103:2071-8.
9. Lee H, Ratajczak MZ. Innate immunity: a key player in the mobilization of hematopoietic stem/progenitor cells. Arch Immunol Ther Exp (Warsz) 2009;57:269-78.
10. Honczarenko M, Ratajczak MZ, Nicholson-Weller A, et al. Complement C3a enhances CXCL12 (SDF-1)-mediated chemotaxis of bone marrow hematopoietic cells independently of C3a receptor. J Immunol 2005;175:3698-706.
11. Wysoczynski M, Reca R, Lee H, et al. Defective engraftment of C3aR-/-hematopoietic stem progenitor cells shows a novel role of the C3a-C3aR axis in bone marrow homing. Leukemia 2009;23:1455-61.
12. Magen E, Mishal J, Paskin J, et al. Resistant arterial hypertension is associated with higher blood levels of complement C3 and C-reactive protein. J Clin Hypertens (Greenwich) 2008;10:677-83.
13. Lee HM, Wu W, Wysoczynski M, et al. Impaired mobilization of hematopoietic stem/progenitor cells in C5-deficient mice supports the pivotal involvement of innate immunity in this process and reveals novel promobilization effects of granulocytes. Leukemia 2009;23:2052-62.
14. Lin A-H, Fukuda N, Jin X-Q, et al. Complement 3 is involved in the synthetic phenotype and exaggerated growth vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 2004;44:42-7.
15. Acostan J, Qin X, Halperin J. Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Curr Pharm Dis 2004;10:203-11.
16. Abbas AK, Lichtman AH, Pober JS. Cellular and molecular immunology, 4th ed. Philadelphia (PA) : WB Saunders Co Inc; 2000.
17. Watts SW. C3 or not C3: that is the question. Hypertension 2004;44:25-6.
18. Giannakopoulos B, Passam F, Rahgozar S, et al. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007;109:422-30.
19. Monsinjon T, Gasque P, Chan P, et al. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J 2003;17:1003-14.
20. Schumacher WA, Fantone JC, Kunkel SE, et al. The anaphylatoxins C3a and C5a are vasodilators in the canine coronary vasculature in vitro and in vivo. Agents Actions 1991;34:345-9.
21. Proctor LM, Moore TA, Monk PN, et al. Complement factors C3a and C5a have distinct hemodynamic effects in the rat. Int Immunopharmacol 2009;9:800-6.
22. Schraufstatter IU, Discipio RG, Zhao M, et al. C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation. J Immunol 2009;182:3827-36.
23. Song MB, Yu XJ, Zhu GX, et al. Transfection of HGF gene enhances endothelial progenitor cell (EPC) function and improves EPC transplant efficiency for balloon-induced arterial injury in hypercholesterolemic rats. Vascul Pharmacol 2009;51:205-13.